Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival

Abstract

Purpose

Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-activated transcription factor, implicated in various aspects of cancer biology, such as differentiation, proliferation, invasion and angiogenesis. The present study aimed to evaluate the clinical significance of PPAR-γ in mobile tongue squamous cell carcinoma (SCC).

Methods

PPAR-γ protein expression was assessed immunohistochemically on 49 mobile tongue SCC tissue samples obtained from an equal number of patients. PPAR-γ expression and intensity of immunostaining were statistically analyzed in relation with clinicopathological characteristics, mitotic index and patients’ survival.

Results

Elevated PPAR-γ expression was more frequently observed in patients with reduced depth of invasion (P = 0.0111). Moderate/intense PPAR-γ staining intensity was more frequently observed in patients with no evidence of muscular infiltration (P = 0.0229) and reduced depth of invasion (P = 0.0176). Mobile tongue SCC patients presenting enhanced PPAR-γ expression had significantly longer overall and disease-free survival times compared to those with low PPAR-γ expression (log-rank test, P = 0.0162 and P = 0.0114, respectively).

Conclusions

PPAR-γ immunoreactivity in mobile tongue SCC was correlated with clinicopathological characteristics crucial for patients’ management and prognosis. PPAR-γ may be considered as a useful prognostic marker in mobile tongue SCC and a potential therapeutic target for tongue cancer chemoprevention and treatment.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. Barnes L, Eveson JW, Reichert P, Sidransky D (2005) World Health Organization classifications tumours, pathology and genetics of head and neck tumours. IARC Press, Lyon

  2. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE (2007) Tongue cancer: is there a difference in survival compared with other subsites in the oral cavity. J Oral Maxillofac Surg 65(2):229–236. doi:10.1016/j.joms.2005.11.094

  3. Blanquicett C, Roman J, Hart CM (2008) Thiazolidinediones as anti-cancer agents. Cancer Ther 6(A):25–34

  4. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky JJ, Hille JJ et al (2005) Oral squamous cell carcinoma: histological risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 29(2):167–178

  5. Brenner H (2002) Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360(9340):1131–1135. doi:10.1016/S0140-6736(02)11199-8

  6. Burgermeister E, Selker R (2007) MAPK kinases as nucleo-cytoplasmic shuttles of PPARγ. Cell Cycle 6(13):1539–2548

  7. Burns KA, Vanden Heuvel JP (2007) Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 1771(8):952–960. doi:10.1016/j.bbalip.2007.04.018

  8. Canto MT, Devesa SS (2002) Oral cavity and pharynx cancer incidence in the United States, 1975–1988. Oral Oncol 38(6):610–617. doi:10.1016/S1368-8375(01)00109-9

  9. Döbrossy L (2005) Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 24(1):9–17. doi:10.1007/s10555-005-5044-4

  10. Giaginis C, Tsantili-Kakoulidou A, Theocharis S (2007) Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 21(3):231–244

  11. Giaginis C, Tsourouflis G, Theocharis S (2008a) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. Curr Mol Med 8(6):562–579

  12. Giaginis C, Tsantili-Kakoulidou A, Theocharis S (2008b) Peroxisome proliferator-activated receptor-gamma ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer. PPAR Res 2008:431763

  13. Giaginis C, Katsamangou E, Tsourouflis G, Zizi-Serbetzoglou D, Kouraklis G, Theocharis S (2009) Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients’ survival. Med Sci Monit 15(5):BR148–156

  14. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics. CA Cancer J Clin 57(1):43–66. doi:10.3322/canjclin.57.1.43

  15. Jiang Y, Zou L, Zhang C, He S, Cheng C, Xu J et al (2009) PPARgamma and Wnt/beta-catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations. J Cancer Res Clin Oncol 135(11):1551–1559. doi:10.1007/s00432-009-0602-8

  16. Kantola S, Parikka M, Jokinen K, Hyrynkangs K, Soini Y, Alho O-P, Salo T (2000) Prognostic factors in tongue cancer-relative importance of demographic, clinical and histopathological factors. Br J Cancer 83(5):614–619. doi:10.1054/bjoc.2000.1323

  17. Kim HJ, Hwang JY, Kim HJ, Choi WS, Kim HJ, Lee JH et al (2007) Expression of a peroxisome proliferator-activated receptor γ1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress. Clin Cancer Res 13(9):2577–2583. doi:10.1158/1078-0432.CCR-06-2062

  18. Klijanienko J, el-Naggar AK, de Braud F, Rodriguez-Peralto JL, Rodriguez R, Itzhaki M et al (1995) Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer 75(7):1649–1656

  19. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Mühldorfer S (2004) Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett’s esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci 49(7–8):1075–1083. doi:10.1023/B:DDAS.0000037790.11724.70

  20. Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B et al (2006) Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 12(21):6444–6451. doi:10.1158/1078-0432.CCR-06-0834

  21. Michalik L, Wahli W (2008) PPARs mediate lipid signaling in inflammation and cancer. PPAR Res 2008:134059. doi:10.1155/2008/134059

  22. Mukunyadzi P, Ai L, Portilla D, Barnes EL, Fan CY (2003) Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases. Mod Pathol 16(12):1218–1223

  23. Mylona E, Giannopoulou I, Diamantopoulou K, Bakarakos P, Nomikos A, Zervas A, Nakopoulou L (2009) Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome. Eur J Surg Oncol 35(2):197–201. doi:10.1016/j.ejso.2008.04.003

  24. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S et al (2009) Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136(4):1242–1250. doi:10.1053/j.gastro.2008.12.048

  25. Ondrey F (2009) Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15(1):2–8. doi:10.1158/1078-0432.CCR-08-0326

  26. Papadaki I, Mylona E, Giannopoulou I, Markaki S, Keramopoulos A, Nakopoulou L (2005) PPARγ expression in breast cancer: clinical value and correlation with ERβ. Histopathology 46(1):37–42

  27. Patel RS, Clark JR, Dirven R, Wyten R, Gao K, O’Brien CJ (2009) Prognostic factors in the surgical treatment of patients with oral carcinoma. ANZ J Surg 79(1–2):19–22. doi:10.1111/j.1445-2197.2008.04791.x

  28. Po Wing Yen A, Lam KY, Wei WI, Lam LK, Ho CM, Chow TL, Yuen WF (2000) A comparison of prognostic significance of tumor diameter, length, width, thickness area, volume and clinicopathological features of oral tongue carcinoma. Am J Surg 180(2):139–143

  29. Po Wing Yen A, Lam KY, Lam LK, Ho CM, Wong A, Chow TL et al (2002) Prognostic factors clinically stage I and II oral tongue carcinoma: a comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score and pathologic features. Head Neck 24(6):513–520

  30. Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID et al (2005) PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab 90(1):463–468. doi:10.1210/jc.2004-1203

  31. Sano D, Myers JN (2007) Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26(3–4):645–662. doi:10.1007/s10555-007-9082-y

  32. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA et al (1999) Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 3(6):799–804. doi:10.1016/S1097-2765(01)80012-5

  33. Shiboski CH, Schmidt BL, Jordan RC (2005) Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer 103(9):1843–1849

  34. Shintani S, Matsuura H, Hasegawa Y, Nakayama B, Fujimoto Y (1997) The relationship of shape of tumor invasion to depth of invasion and cervical lymph node metastasis in squamous cell carcinoma of the tongue. Oncology 54(6):463–467

  35. Takahashi H, Fujita K, Fujisawa T, Yonemitsu K, Tomimoto A, Ikeda I et al (2006) Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. Cancer Sci 97(9):854–860

  36. Takashima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T, Otani S (2001) PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 19(3):465–471

  37. Takashima T, Fujiwara Y, Hamaguchi M, Sasaki E, Tominaga K, Watanabe T et al (2005) Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma. Oncol Rep 13(4):601–606

  38. Terashita Y, Sasaki H, Haruki N, Nishiwaki T, Ishiguro H, Shibata Y et al (2002) Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol 32(7):238–243

  39. Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, Koutselinis A (2002) Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 36(3):249–255

  40. Theocharis S, Giaginis C, Parasi A, Margeli A, Kakisis J, Agapitos E, Kouraklis G (2007) Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients’ survival. Dig Dis Sci 52(9):2305–2311

  41. Tímár J, Csuka O, Remenár E, Répássy G, Kásler M (2005) Progression of head and neck squamous cell cancer. Cancer Metastasis Rev 24(1):107–127. doi:10.1007/s10555-005-5051-5

  42. Wangsa D, Ryott M, Avall-Lundquist E, Petersson F, Elmberg G, Luo J et al (2008) Ki-67 expression predicts locoregional recurrence in stage I oral tongue carcinoma. Br J Cancer 99(7):1121–1128. doi:10.1038/sj.bjc.6604633

  43. Yoshida K, Hirose Y, Tanaka T, Yamada Y, Kuno T, Kohno H et al (2003) Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci 94(4):365–371

  44. Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE (2005) Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer 92(1):113–119. doi:10.1038/sj.bjc.6602244

Download references

Conflict of interest statement

No conflict of interest.

Author information

Correspondence to Stamatios Theocharis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Theocharis, S., Klijanienko, J., Giaginis, C. et al. Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Cancer Res Clin Oncol 137, 251–259 (2011). https://doi.org/10.1007/s00432-010-0882-z

Download citation

Keywords

  • PPAR-γ
  • Mobile tongue
  • Squamous cell carcinoma
  • Clinicopathological parameters
  • Prognosis
  • Immunohistochemistry